New Antibody-Like drug joins forces with standard chemo to fight lung cancer
NCT ID NCT06077500
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This early-phase trial tests a new drug called BI 764532 (obrixtamig) added to standard chemotherapy and immunotherapy for people with extensive-stage small cell lung cancer. The main goal is to find the highest safe dose of BI 764532 when given with standard treatments. About 46 adults will receive the combination as intravenous infusions, and researchers will monitor side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA (SCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AZ Groeninge
Kortrijk, 8500, Belgium
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Emory University
Atlanta, Georgia, 30322, United States
-
Fundación Jiménez Díaz
Madrid, 28040, Spain
-
HOP Civil
Strasbourg, 67091, France
-
Hamamatsu University Hospital
Shizuoka, Hamamatsu, 431-3192, Japan
-
Hospital Universitario Ramon Y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Virgen De La Macarena
Seville, 41009, Spain
-
Hôpital Louis Pradel
Bron, 69677, France
-
INS Bergonie
Bordeaux, 33000, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Instituto Valenciano de Oncología
Valencia, 46009, Spain
-
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, 135-8550, Japan
-
MED POLONIA SP Z O O, Clinical Trials Department,Poznan
Poznan, 60-693, Poland
-
Medical University Gdansk
Gdansk, 80-214, Poland
-
National Cancer Center Hospital
Tokyo, Chuo-ku, 104-0045, Japan
-
Orlando Health Cancer Institute
Orlando, Florida, 32806, United States
-
Polish Mother's Memorial Hospital - Research Institute
Lodz, 93-338, Poland
-
Saitama Medical University International Medical Center
Saitama, Hidaka, 350-1298, Japan
-
University Hospital of Lausanne
Lausanne, 1011, Switzerland
-
Universitätsklinikum Gießen und Marburg GmbH
Giessen, 35392, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 764532 (obrixtamig) plus carboplatin, etoposide, and atezolizumab
What this could lead to
If it works, this could point toward a more effective first-line treatment for extensive-stage small cell lung cancer.
What could go wrong
This is an early Phase 1 trial with only 46 participants, focused on safety and dosing. The combination may cause significant side effects and may not improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.